Health X Platform financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹447cr+49.7% on Q1 FY26
Net profit
₹2.0cr−92.5% on Q1 FY26
EBITDA margin
−1.9%−3.9 pts on Q1 FY26
EPS
₹0.80−89.4% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue447298+49.7%
EBITDA−8.46.1—
EBITDA margin−1.9%2.0%−3.9 pts
Profit before tax2.030.2−93.5%
Net profit2.026.6−92.5%
EPS₹0.80₹7.52−89.4%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹447 crNet profit₹2.0 crNet margin0.4%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
887————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
30.230.212.433.631.7
124124195——
22.122.10.00.00.0
1,003————
1,4681,3191,1111,3761,040
—+18.8%−19.2%+32.3%—
−66.5−52.1−56.05.4−44.0
−4.5%−4.0%−5.0%0.4%−4.2%
−73.9−58.7−61.9−3.7−52.2
−26.1−1.4−1345.9−99.5
−1.8%−0.1%−12.0%0.4%−9.6%
−₹6.35₹0.37−₹28.66₹2.79−₹22.70
—+101.3%−1,126.3%+112.3%—
—−73.8−17.338.2−104
—−14.9−10.4−14.2−27.9
−88.8−88.8−27.723.9−132
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HEALTHX₹278.80

Health X Platform Limited

· Pharma & Health
₹ CrorePeersSURAKSHAKRSNAANEPHROPLUS3BBLACKBIOMcap ₹887 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————886.9
- Cash, Equiv & ST Investments31.733.612.430.230.2
+ Minority Interest——194.7124.4124.4
+ Total Debt0.00.00.022.122.1
Enterprise Value————1,003.2
Revenue1,039.81,375.71,111.01,319.31,467.7
Growth %, YoY—+32.3-19.2+18.8—
EBITDA-44.05.4-56.0-52.1-66.5
Margin %-4.230.39-5.04-3.95-4.53
EBIT-52.2-3.7-61.9-58.7-73.9
Net Income-99.55.9-133.5-1.4-26.1
Margin %-9.570.43-12.02-0.11-1.78
EPS, Adj (current shares)-22.702.79-28.660.37-6.35
Growth %, YoY—+112.3-1,126.3+101.3—
Cash from Operations-104.538.2-17.3-73.8—
Capital Expenditures-27.9-14.2-10.4-14.9—
Free Cash Flow-132.423.9-27.7-88.8-88.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Health X Platform financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Health X Platform (NSE: HEALTHX) had a market capitalisation of ₹888 crore at the 29 October 2026 close (₹279.20 a share) and a price-to-book ratio of 1.39. In FY26 its consolidated net profit attributable to shareholders was ₹1.2 crore on revenue of ₹1,319 crore; in Q1 FY27 (April–June 2026) it was ₹2.5 crore, down 89.4% year on year. Its debt-to-equity ratio was 0.03 on 31 March 2026. Promoters held 74.07% of the shares on 30 September 2026.

Share price used
₹279.20 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Health X Platform at a glance · consolidated

Market cap
₹888 Crat ₹279.20 · 29 Oct close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
1.39book value ₹201.47 a share
ROE (FY26)
0.2%
Debt to equity
0.03net cash ₹8.1 Cr
Promoter holding
74.07%unchanged vs 30 Jun 202630 September 2026
Net worth
₹641 Cr−4.3% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹88.8 Cr
EPS (FY26)
₹0.37

Questions

What is the Health X Platform PE ratio today?

Health X Platform's PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit attributable to shareholders over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹20.2 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹888 crore at ₹279.20 a share.

What is the Health X Platform PB ratio (price to book value)?

Health X Platform's price-to-book (PB) ratio is 1.39 at the 29 October 2026 close: a market capitalisation of ₹888 crore divided by shareholders' equity (book value) of ₹641 crore on 31 March 2026. That is a book value of ₹201.47 per share against a share price of ₹279.20.

What is the Health X Platform debt to equity ratio?

Health X Platform's debt-to-equity ratio was 0.03 on 31 March 2026: borrowings, debt securities, deposits and subordinated debt of ₹22.1 crore against total equity of ₹765 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Health X Platform market cap?

Health X Platform's market capitalisation was ₹888 crore at the 29 October 2026 close: 3.18 crore shares at ₹279.20 each.

Is Health X Platform debt free?

No. Health X Platform had borrowings of ₹22.1 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.03. Its cash and current investments were ₹30.2 crore, so it held net cash of ₹8.1 crore.

What is the Health X Platform EPS?

Health X Platform's basic earnings per share (EPS) were ₹0.37 in FY26. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to −₹6.35.

What is the Health X Platform net worth?

Health X Platform's net worth — shareholders' equity in its consolidated balance sheet — was ₹641 crore on 31 March 2026, down 4.3% from ₹670 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹888 crore at the 29 October 2026 close.

What is the Health X Platform promoter holding?

Promoters held 74.07% of Health X Platform on 30 September 2026, unchanged from the previous quarter and down 0.17 percentage points from 74.24% a year earlier, according to the shareholding pattern filed with NSE.

What is the Health X Platform free cash flow?

In FY26, Health X Platform generated ₹73.8 crore of cash from operations and spent ₹14.9 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹88.8 crore. In FY25 it was −₹27.7 crore.

What is the Health X Platform ROE and ROCE?

In FY26, Health X Platform's return on equity (ROE) was 0.2%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year).

What is the Health X Platform revenue and profit in FY26?

In FY26 (April 2025–March 2026), Health X Platform's consolidated net profit attributable to shareholders was ₹1.2 crore, against a loss of ₹91.2 crore in FY25, on revenue from operations of ₹1,319 crore (up 18.8%).

When are the Health X Platform next results?

Health X Platform has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the Health X Platform book value per share?

Health X Platform's book value per share was ₹201.47 on 31 March 2026: shareholders' equity of ₹641 crore divided by the 3.18 crore shares in issue, down 4.3% from ₹210.58 a year earlier. The share price at the 29 October 2026 close was ₹279.20.

What is the Health X Platform shareholding pattern?

On 30 September 2026, Health X Platform's shares were held by promoters 74.07%, foreign portfolio investors (FII/FPI) 2.32%, domestic institutions (DII) 2.61% and retail and other non-institutional investors 21.00%. Over the year, FII holding was up 0.28 percentage points from 2.04% and DII holding was up 0.54 percentage points from 2.07%.

What are the Health X Platform latest quarterly results?

Health X Platform's latest results are for Q1 FY27 (April–June 2026), filed on 7 August 2026: consolidated net profit attributable to shareholders ₹2.5 crore, down 89.4% from ₹23.9 crore in Q1 FY26; revenue from operations ₹447 crore, up 49.7% year on year.

How does Health X Platform compare with its peers?

On FY26 consolidated figures, against Suraksha Diagnostic, Krsnaa Diagnostics and Nephrocare Health Services: Health X Platform's operating margin of −4.5% is the lowest of the four (Suraksha Diagnostic 17.4%, Krsnaa Diagnostics 15.7%, Nephrocare Health Services 13.7%; peer average 15.6%); its return on equity of 0.2% is the lowest of the four (Suraksha Diagnostic 14.1%, Krsnaa Diagnostics 10.9%, Nephrocare Health Services 6.9%; peer average 10.6%).

How does the Health X Platform PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Health X Platform's PE ratio is 755.3, the highest of the four: Suraksha Diagnostic 51.7, Krsnaa Diagnostics 15.9 and Nephrocare Health Services 82.1, a peer average of 49.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Health X Platform vs Suraksha Diagnostic: how do they compare?

In FY26, Health X Platform earned net profit attributable to shareholders of ₹1.2 crore on revenue of ₹1,319 crore, against ₹32.2 crore on ₹310 crore for Suraksha Diagnostic. Health X Platform's operating margin was −4.5% (Suraksha Diagnostic 17.4%) and its return on equity 0.2% (Suraksha Diagnostic 14.1%). At the 29 October 2026 close, Health X Platform's market capitalisation was ₹888 crore against ₹1,664 crore for Suraksha Diagnostic, and its PE ratio on FY26 profit 755.3 against 51.7.

Where do these Health X Platform figures come from?

From Health X Platform's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.